A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mannkind Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 102,100 shares of MNKD stock, worth $698,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,100
Previous 64,300 58.79%
Holding current value
$698,364
Previous $335,000 91.34%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.01 - $6.7 $2.87 Million - $3.84 Million
-572,608 Reduced 33.6%
1,131,383 $7.11 Million
Q2 2024

Aug 14, 2024

BUY
$4.05 - $5.43 $2.86 Million - $3.83 Million
705,133 Added 70.59%
1,703,991 $8.89 Million
Q1 2024

May 15, 2024

SELL
$3.25 - $5.27 $85,338 - $138,379
-26,258 Reduced 2.56%
998,858 $4.52 Million
Q4 2023

Feb 14, 2024

SELL
$3.34 - $4.29 $2.75 Million - $3.53 Million
-823,142 Reduced 44.54%
1,025,116 $3.73 Million
Q3 2023

Nov 14, 2023

BUY
$3.91 - $5.45 $1.75 Million - $2.45 Million
448,829 Added 32.07%
1,848,258 $7.63 Million
Q2 2023

Aug 14, 2023

SELL
$3.72 - $4.79 $5.2 Million - $6.7 Million
-1,397,720 Reduced 49.97%
1,399,429 $5.7 Million
Q1 2023

May 15, 2023

SELL
$3.95 - $5.63 $5.34 Million - $7.61 Million
-1,352,553 Reduced 32.59%
2,797,149 $11.5 Million
Q4 2022

Feb 14, 2023

BUY
$3.02 - $5.37 $8.09 Million - $14.4 Million
2,679,299 Added 182.22%
4,149,702 $21.9 Million
Q3 2022

Nov 14, 2022

BUY
$2.99 - $4.35 $2.23 Million - $3.25 Million
746,937 Added 103.24%
1,470,403 $4.54 Million
Q2 2022

Aug 15, 2022

SELL
$2.67 - $4.77 $1.24 Million - $2.22 Million
-466,272 Reduced 39.19%
723,466 $2.76 Million
Q1 2022

May 16, 2022

BUY
$2.62 - $4.45 $2.02 Million - $3.44 Million
772,784 Added 185.34%
1,189,738 $4.38 Million
Q4 2021

Feb 14, 2022

SELL
$4.05 - $5.37 $2.56 Million - $3.39 Million
-631,647 Reduced 60.24%
416,954 $1.82 Million
Q3 2021

Nov 15, 2021

BUY
$3.89 - $5.48 $1.09 Million - $1.54 Million
280,436 Added 36.51%
1,048,601 $4.56 Million
Q2 2021

Aug 16, 2021

SELL
$3.61 - $5.45 $11.9 Million - $17.9 Million
-3,291,650 Reduced 81.08%
768,165 $4.19 Million
Q1 2021

May 17, 2021

BUY
$3.14 - $6.14 $10.5 Million - $20.6 Million
3,356,590 Added 477.31%
4,059,815 $15.9 Million
Q4 2020

Feb 16, 2021

BUY
$1.79 - $4.04 $123,295 - $278,275
68,880 Added 10.86%
703,225 $2.2 Million
Q3 2020

Nov 16, 2020

BUY
$1.56 - $2.08 $536,601 - $715,468
343,975 Added 118.46%
634,345 $1.19 Million
Q2 2020

Aug 14, 2020

BUY
$0.94 - $2.21 $161,100 - $378,756
171,383 Added 144.04%
290,370 $508,000
Q1 2020

May 15, 2020

BUY
$0.84 - $1.76 $52,400 - $109,790
62,381 Added 110.2%
118,987 $123,000
Q4 2019

Feb 14, 2020

SELL
$1.14 - $1.49 $39,032 - $51,016
-34,239 Reduced 37.69%
56,606 $73,000
Q3 2019

Nov 14, 2019

SELL
$1.04 - $1.44 $15,448 - $21,389
-14,854 Reduced 14.05%
90,845 $113,000
Q2 2019

Aug 14, 2019

BUY
$1.09 - $1.88 $94,535 - $163,052
86,730 Added 457.22%
105,699 $122,000
Q4 2018

Feb 14, 2019

SELL
$1.02 - $2.05 $44,502 - $89,441
-43,630 Reduced 69.7%
18,969 $20,000
Q3 2018

Nov 13, 2018

BUY
$1.01 - $2.19 $45,849 - $99,417
45,396 Added 263.88%
62,599 $0
Q2 2018

Aug 10, 2018

BUY
$1.59 - $2.38 $27,352 - $40,943
17,203 New
17,203 $0

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.76B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.